These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 8903475

  • 21. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
    Wang J, Qu H, Jin L, Zeng W, Qin L, Zhang F, Wei X, Lu W, Zhang C, Liang W.
    J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
    [Abstract] [Full Text] [Related]

  • 22. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.
    Zeng X, Morgenstern R, Nyström AM.
    Biomaterials; 2014 Jan; 35(4):1227-39. PubMed ID: 24210875
    [Abstract] [Full Text] [Related]

  • 23. TNF-induced apoptosis in multidrug resistant friend erythroleukemia is not influenced by the P-glycoprotein and glutathione status of the cell line.
    Flugy A, Borsellino N, D'Alessandro N.
    Oncol Res; 1995 Jan; 7(10-11):559-64. PubMed ID: 8866668
    [Abstract] [Full Text] [Related]

  • 24. Doxorubicin induces prostate cancer drug resistance by upregulation of ABCG4 through GSH depletion and CREB activation: Relevance of statins in chemosensitization.
    Mallappa S, Neeli PK, Karnewar S, Kotamraju S.
    Mol Carcinog; 2019 Jul; 58(7):1118-1133. PubMed ID: 30834613
    [Abstract] [Full Text] [Related]

  • 25. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
    Trail PA, Willner D, Knipe J, Henderson AJ, Lasch SJ, Zoeckler ME, TrailSmith MD, Doyle TW, King HD, Casazza AM, Braslawsky GR, Brown J, Hofstead SJ, Greenfield RS, Firestone RA, Mosure K, Kadow KF, Yang MB, Hellström KE, Hellström I.
    Cancer Res; 1997 Jan 01; 57(1):100-5. PubMed ID: 8988048
    [Abstract] [Full Text] [Related]

  • 26. Transferrin as a drug carrier: Cytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin conjugate in the human leukemia cells.
    Szwed M, Matusiak A, Laroche-Clary A, Robert J, Marszalek I, Jozwiak Z.
    Toxicol In Vitro; 2014 Mar 01; 28(2):187-97. PubMed ID: 24055890
    [Abstract] [Full Text] [Related]

  • 27. Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin.
    Awasthi S, Cheng J, Singhal SS, Saini MK, Pandya U, Pikula S, Bandorowicz-Pikula J, Singh SV, Zimniak P, Awasthi YC.
    Biochemistry; 2000 Aug 08; 39(31):9327-34. PubMed ID: 10924126
    [Abstract] [Full Text] [Related]

  • 28. Characterization of new potential anticancer drugs designed to overcome glutathione transferase mediated resistance.
    Johansson K, Ito M, Schophuizen CM, Mathew Thengumtharayil S, Heuser VD, Zhang J, Shimoji M, Vahter M, Ang WH, Dyson PJ, Shibata A, Shuto S, Ito Y, Abe H, Morgenstern R.
    Mol Pharm; 2011 Oct 03; 8(5):1698-708. PubMed ID: 21851097
    [Abstract] [Full Text] [Related]

  • 29. A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance.
    Bidwell GL, Davis AN, Fokt I, Priebe W, Raucher D.
    Invest New Drugs; 2007 Aug 03; 25(4):313-26. PubMed ID: 17483874
    [Abstract] [Full Text] [Related]

  • 30. Alterations in glutathione and glutathione-related enzymes in a multidrug-resistant small cell lung cancer cell line.
    Cole SP, Downes HF, Mirski SE, Clements DJ.
    Mol Pharmacol; 1990 Feb 03; 37(2):192-7. PubMed ID: 1968221
    [Abstract] [Full Text] [Related]

  • 31. Preparation and functional evaluation of new doxorubicin immunoconjugates containing an acid-sensitive linker on small-cell lung cancer cells.
    Froesch BA, Stahel RA, Zangemeister-Wittke U.
    Cancer Immunol Immunother; 1996 Jan 03; 42(1):55-63. PubMed ID: 8625367
    [Abstract] [Full Text] [Related]

  • 32. Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation.
    van Wijngaarden J, van Beek E, van Rossum G, van der Bent C, Hoekman K, van der Pluijm G, van der Pol MA, Broxterman HJ, van Hinsbergh VW, Löwik CW.
    Eur J Cancer; 2007 Jan 03; 43(2):433-42. PubMed ID: 17097285
    [Abstract] [Full Text] [Related]

  • 33. Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer.
    Singhal SS, Singhal J, Nair MP, Lacko AG, Awasthi YC, Awasthi S.
    Int J Oncol; 2007 Mar 03; 30(3):717-25. PubMed ID: 17273774
    [Abstract] [Full Text] [Related]

  • 34. [A new method for the intravital assessment of the functional activity of the membrane transporters performing the efflux of antitumor preparations from the cells of solid tumor specimens].
    Bogush TA, Smirnova GB, Bogush EA, Robert J.
    Antibiot Khimioter; 1999 Mar 03; 44(2):19-24. PubMed ID: 10202553
    [Abstract] [Full Text] [Related]

  • 35. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S.
    Cancer Res; 2005 Feb 15; 65(4):1541-6. PubMed ID: 15735043
    [Abstract] [Full Text] [Related]

  • 36. The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines.
    Kostrzewa-Nowak D, Paine MJ, Wolf CR, Tarasiuk J.
    Br J Cancer; 2005 Jul 11; 93(1):89-97. PubMed ID: 15942634
    [Abstract] [Full Text] [Related]

  • 37. Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia.
    Colombo T, Gonzalez Paz O, D'Incalci M.
    Br J Cancer; 1996 Apr 11; 73(7):866-71. PubMed ID: 8611397
    [Abstract] [Full Text] [Related]

  • 38. Screening of biochemical modulator by tumor cell permeability of doxorubicin.
    Sadzuka Y, Hatakeyama H, Daimon T, Sonobe T.
    Int J Pharm; 2008 Apr 16; 354(1-2):63-9. PubMed ID: 18054183
    [Abstract] [Full Text] [Related]

  • 39. Methionine depletion enhances the antitumoral efficacy of cytotoxic agents in drug-resistant human tumor xenografts.
    Poirson-Bichat F, Gonçalves RA, Miccoli L, Dutrillaux B, Poupon MF.
    Clin Cancer Res; 2000 Feb 16; 6(2):643-53. PubMed ID: 10690550
    [Abstract] [Full Text] [Related]

  • 40. Intracellular glutathione level and efflux in human melanoma and cervical cancer cells differing in doxorubicin resistance.
    Drozd E, Gruber B, Marczewska J, Drozd J, Anuszewska E.
    Postepy Hig Med Dosw (Online); 2016 Apr 18; 70():319-28. PubMed ID: 27117108
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.